An observational study in ARDS (Acute Respiratory Distress Syndrome), sponsored by Prenosis, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Prenosis, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.
Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 3rd largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2026, is one of 23 observational ones, reaches primary completion later than 13 of the 18 other live ones, and was the 110th registered.
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
Browse Acute Lung Injury studies →17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Implicit Bioscience · Sites in United States
Ages 18+
HTIC, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
University of Kentucky · Sites in United States
Ages 18–99 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 42 · Phase 3 17 · Phase 4 4
First in 2001; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 100 across 131 observational studies indexed under Acute Lung Injury.
Median enrollment 68 across the 88 interventional studies, 135 across the 22 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 112 have an industry lead sponsor. The 10 most frequent:
Prenosis, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Prenosis, Inc. has 1 study filed under Acute Lung Injury — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Lung Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125079University of PennsylvaniaLung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy. | 2026-12-20 |
| NCT07449572HTIC, IncClinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS | 2027-01 |
| NCT06476132National Institute of Allergy and Infectious Diseases (NIAID)Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients | 2027-05-30 |
| NCT04068012Children's Hospital Los AngelesClinical Decision Support Tool in PARDS Pilot Study | 2027-07 |
| NCT05977153The University of Texas Medical Branch, GalvestonCT for Personalized Mechanical Ventilation | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies in Acute Lung Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to establish a centralized ARDS biorepository of longitudinal biospecimens and harmonized clinical data, develop unsupervised, therapy-agnostic endotyping algorithms, and develop unsupervised, therapy-specific treatment-prediction algorithms over a 24 month period.
Adults with clinically defined acute respiratory distress syndrome (ARDS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-intubated ARDS: PaO2:FIO2\<300mmHg or SpO2:FIO2\<315 (if SpO2\<97%) on HFNO with flow of >30 L/min or NIV/CPAP with at least 5 cm H2O end-expiratory pressure; or Intubated ARDS: PaO2:FIO2\<300 mm Hg or SpO2:FIO2\<315 (if SpO2\<97%)
Exclusion Criteria:
Number of Participants with an ARDS Diagnosis
Adults with clinically defined ARDS receiving ICU-level care
Time frame: from enrollment to 28-day in-hospital mortality
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.
Of 46 observational studies under Acute Lung Injury, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 27 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Sep 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prenosis, Inc.